Wei S, et al. (2013) Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 32, 1110-20 22525275

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S166-p - MDM2 (human) ▲

Modsite: SsRRRAIsEtEENsD SwissProt Entrez-Gene Orthologous residues MDM2 (human): S166‑p, MDM2 (mouse): S163‑p, MDM2 (rat): S138‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma, lymphoma, Burkitt's lymphoma Relevant cell lines - cell types - tissues:  MDST8 (intestinal), Namalwa (B lymphocyte) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE Akt1 (human) activation of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes lenalidomide increase lenalidomide PPP2CA (human) inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  intracellular localization, protein stabilization Comments:  inhibits autoubiquitination and promotes nuclear localization of MDM2

S186-p - MDM2 (human) ▲

Modsite: RQRkRHksDsIsLsF SwissProt Entrez-Gene Orthologous residues MDM2 (human): S186‑p, MDM2 (mouse): S183‑p, MDM2 (rat): A158‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma, lymphoma, Burkitt's lymphoma Relevant cell lines - cell types - tissues:  MDST8 (intestinal), Namalwa (B lymphocyte) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE Akt1 (human) activation of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes lenalidomide increase lenalidomide PPP2CA (human) inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  intracellular localization, protein stabilization Comments:  inhibits autoubiquitination and promotes nuclear localization of MDM2

S46-p - p53 (human) ▲

Modsite: AMDDLMLsPDDIEQW SwissProt Entrez-Gene Orthologous residues p53 (human): S46‑p, p53 iso2 (human): S46‑p, p53 iso4 (human): S7‑p, p53 (mouse): ‑, p53 iso2 (mouse): ‑, p53 (rat): ‑, p53 (rabbit): S45‑p, p53 (green monkey): S46‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma, lymphoma, Burkitt's lymphoma Relevant cell lines - cell types - tissues:  MDST8 (intestinal), Namalwa (B lymphocyte) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes lenalidomide increase lenalidomide PPP2CA (human) inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  protein degradation

T55-p - p53 (human) ▲

Modsite: DDIEQWFtEDPGPDE SwissProt Entrez-Gene Orthologous residues p53 (human): T55‑p, p53 iso2 (human): T55‑p, p53 iso4 (human): T16‑p, p53 (mouse): E55‑p, p53 iso2 (mouse): E55‑p, p53 (rat): E57‑p, p53 (rabbit): N54‑p, p53 (green monkey): T55‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma, lymphoma, Burkitt's lymphoma Relevant cell lines - cell types - tissues:  MDST8 (intestinal), Namalwa (B lymphocyte) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes lenalidomide increase lenalidomide PPP2CA (human) inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  protein degradation